Please login to the form below

Not currently logged in
Email:
Password:

Dr Thomas Lynch Jnr takes up new role at Bristol-Myers Squibb

Will focus on leading the firm's research and development programme

Dr Thomas Lynch JnrBristol-Myers Squibb (BMS) has appointed Dr Lynch as executive vp and chief scientific officer, a role that will see him focus on leading the firm’s research and development programme.

He previously served on the firm's board of directors and succeeds Dr Francis Cuss who will retire from the company.

Dr Lynch said: “I have seen first-hand Bristol-Myers Squibb’s commitment to making a meaningful difference in the lives of patients, and I am honoured to lead the company’s R&D programme.

“I am confident that our team will continue to discover and develop innovative medicines that address serious diseases in areas of significant unmet medical need.”

Dr Lynch has more than 30 years medical, management and leadership experience and joined BMS in 2013 from the Yale Cancer Center.

Giovanni Caforio, chief executive officer at Bristol-Myers Squibb, added: “Tom brings deep industry knowledge and a sophisticated understanding of the Bristol-Myers Squibb research and development programme from his experience as a member of our Board.

“As we transition to our next phase of growth, we are confident Tom is the right person to lead our dynamic R&D organisation as we focus on accelerating the development of our immuno-oncology medicines.”

28th March 2017

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics